AKAhmed Khattak

Ahmed Khattak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmed Khattak has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A tertiary centre experience of robotic Aquablation: Standard operating versus high-intensity theatre protocol

    by Ahmed Khattak, Ritika Sundaram, Nisha Pindoria, Sachin Malde, Oussama Elhage, Rick Popert, Jonathan Noël

    Objective: Aquablation is FDA and NICE approved for treating benign prostatic hyperplasia (BPH). In the UK, increasing surgical elective waiting lists have created the need for HIT list models. We present a tertiary centre experience using Aquablation within a HIT list framework and compare it to standard operating protocol (SOP). Methods: A prospective cohort study was performed with 60 patients awaiting bladder outlet surgery. Ten patients were operated using HIT protocol and compared to 50 patients under SOP. We assessed differences in perioperative outcomes and complications, including postoperative follow-up. Results: There was a significant decrease in IPSS from 24.92 to 5.93 ( p = 0.001) and 93% ejaculation preservation. A significant difference in postoperative Hb decrease was observed, with HIT = 5.3 g/L vs SOP = 12.3 g/L ( p < 0.05). No blood transfusions were needed. Operative times were similar, with the HIT group having a median of 56 minutes and the SOP group 59 minutes. Conclusion: Our analysis demonstrates that the introduction of Aquablation in a tertiary centre is feasible for managing moderately enlarged prostate glands (80–150 ml). The implementation of a dual operating theatre HIT list using a single Aquabeam robotic system appears to be a viable strategy for increasing surgical capacity. While initial results suggest comparable perioperative outcomes to standard operating protocol, further studies with larger cohorts are required to assess the long-term safety and broader applicability of this approach. Level of evidence: 3

  • Artificial intelligence‐driven streamlining of prostate cancer multidisciplinary team recommendations in a tertiary NHS centre in the UK

    by Ahmed Khattak, Danny Ruta, Vivek Patkar, Rick Popert, Jonathan Makanjuola, Martha Martin, Lesedi Ledwaba‐Chapman, Kate Dodgson, Robert Oldroyd, Jonathan Noel, et al.

    Objectives: To evaluate the effectiveness of a rules‐based artificial intelligence (AI) clinical decision support system (CDSS) called the PROState AI Cancer‐Decision Support (PROSAIC‐DS) in streamlining the prostate cancer multidisciplinary team (MDT) pathway by identifying patients meeting standard of care (SoC) guidelines for reduced discussion in MDT meetings.Subjects/Patients and Methods: This study consisted of two phases. Phase one involved a retrospective concordance analysis of 287 patients referred to the prostate MDT at King's College Hospital over a 2‐year period. In phase two, a prospective analysis included 416 patients from Guy's Hospital over another 2‐year period. Clinical treatment recommendations were independently reviewed by a panel of urologists and oncologists to establish a ‘ground truth.’ Concordance between the medical recommendations and those generated by the PROSAIC‐DS was assessed.Results: In phase one, the overall concordance between the clinicians’ recommendations and the PROSAIC‐DS was 92% (95% confidence interval [CI] 88.1–94.7%), compared to just 53% (95% CI 47–59%) with historic MDT outputs (P < 0.01). In phase two, the PROSAIC‐DS achieved an 85.6% concordance (95% CI 81.6–88.9%) with the MDT recommendations for 355 evaluable cases (P < 0.01). Notably, using a machine learning‐derived decision tree enabled the identification of 93 patients for streamlined management, demonstrating a 97.8% concordance in this subgroup (P < 0.01).Conclusion: The implementation of the PROSAIC‐DS into the prostate cancer MDT pathway allowed 33.8% of patients to bypass MDT discussions with high treatment concordance. This study showcases the potential for AI‐based solutions to improve clinical workflow and patient management in oncology, thus addressing the workload challenges faced by MDTs.


  • Open Access

    The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database

    by Sara Baldini, Ahmed Khattak, Paolo Capogrosso, Gabriele Antonini, Federico Dehò, Fabrizio Schifano, Nicolò Schifano

    Background: A wide range of medications may have a possible role in the development of male-factor infertility (MFI), including various antineoplastic agents, testosterone/anabolic steroids, immunosuppressive drugs/immunomodulators, glucocorticosteroids, non-steroidal anti-inflammatory drugs, opiates, antiandrogenic drugs/5-alpha-reductase inhibitors, various antibiotics, antidepressants, antipsychotics, antiepileptic agents and others. We aimed at investigating this issue from a pharmacovigilance-based perspective. Methods: The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried to identify the drugs associated the most with MFI individual reports. Only those drugs being associated with more than 10 MFI reports were considered for the disproportionality analysis. Proportional Reporting Ratios (PRRs) and their confidence intervals were computed for all the drugs identified in this way in January 2023. Secondary, ‘unmasking’, dataset analyses were carried out as well. Results: Out of the whole database, 955 MFI reports were identified, 408 (42.7%) of which were associated with 20 medications, which had more than 10 reports each. Within this group, finasteride, testosterone, valproate, diethylstilbestrol, mechloretamine, verapamil, lovastatin and nifedipine showed significant levels of actual disproportionate reporting. Out of these, and before unmasking, the highest PRR values were identified for finasteride, diethylstilbestrol and mechloretamine, respectively, with values of 16.0 (12.7–20.3), 14.3 (9.1–22.4) and 58.7 (36.3–95.9). Conclusions: A variety of several medications, a number of which were already supposed to be potentially linked with MFI based on the existing evidence, were associated with significant PRR levels for MFI in this analysis. A number of agents which were previously hypothesized to be associated with MFI were not represented in this analysis, suggesting that drug-induced MFI is likely under-reported to regulatory agencies. Reproductive medicine specialists should put more effort into the detection and reporting of these adverse drug reactions.


  • Open Access

    Contemporary Management of Chronic Prostatitis

    by Ahmed S. Khattak, Nicholas Raison, Arie Hawazie, Azhar Khan, Oliver Brunckhorst, Kamran Ahmed

    Chronic prostatitis (CP) is a common condition, yet remains a challenge to treat in clinical practice due to the heterogeneity of symptoms. The aim of this article is to undertake a narrative review using key research papers in this field in order to develop a treatment algorithm and research recommendations for the management of type II and type III prostatitis taking a broader look at interventions beyond those recommended in the European Association of Urology Guidelines. A search was performed using multiple databases and trial registries with no language restrictions. Searches were completed on March 1, 2021, with a focus on randomized controlled trials (RCTs), meta-analyses, and systematic reviews. However, in areas with a dearth of such studies, we included case series and observational studies, thus allowing us to assess current levels of evidence and areas of potential research. We identified and reviewed 63 studies. The level of evidence and the quality of trials were assessed and reported. Research recommendations, where applicable, were also highlighted. CP/chronic pelvic pain syndrome (CPPS) is a heterogenous term referring to diverse symptomology that requires tailored treatments depending on the patients’ complaints. After a review of the evidence available, we present a treatment algorithm that is based on the much-discussed UPOINT (urinary symptoms, psychosocial dysfunction, organ-specific findings, infection, neurologic/systemic, and tenderness of muscles) framework. Future studies should focus on multimodal therapy based on such frameworks and provide the future direction of this complex condition.


  • Open Access

    Re: Uretero-inguinal hernia with obstructive urolithiasis

    by Ahmed Khattak, Oladapo Feyisetan, Michael S. Floyd Jr., Azizan Samsudin

    We read with interest the recent radiology page publication by Rathburn et al. highlighting the case of a 64 year old male with prostate cancer who was incidentally found to have left hydronephrosis and renal impairment during staging. Formal computed tomography revealed a 1cm stone in his distal left ureter which was located within an inguinoscrotal hernia and his right distal ureter was also contained within the right inguinoscrotal hernia (1).